Patents

Lophoras IP portfolio includes a composition of matter patent covering a wide area of chemical space encompassing millions of novel compounds within a novel compound class of phenethylamine derived psychedelics- granted in the US, Europe and elsewhere.

Furthermore, Lophora controls the rights to the proprietary manufacture of lead candidate LPH-5 and fast follower LPH-48, including protection of the novel salt and polymorphic form of both compounds.

Patent family “Selective 5-HT2A agonists”
International filing date: 6 November 2020. 

Composition of matter patent covering a new class of small molecules with selective 5-HT2A agonism. Compound claims encompass chemical space of >1B compounds. Medical use claims on a wide range of indications applicable to psychedelics.

  • Australia
  • Brazil
  • Canada
  • China (Granted 13 February 2024)
  • Europe (Granted 31 May 2023)
    In force in Albania, Austria, Bosnia & Herzegovina, Belgium, Bulgaria, Switzerland, Cyprus, Czech Republic, Germany, Denmark, Spain, Finland, France, United Kingdom, Greece, Croatia, Hungary, Ireland, Iceland, Italy, Cambodia, Lithuania, Luxembourg, Latvia, Morocco, Monaco, Republic of Moldova, Montenegro, The Former Yugoslav Republic of Macedonia, Malta, Netherlands, Norway, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia, Tunisia & Turkey
  • Hong Kong
  • India
  • Israel (Granted 3 July 2023)
  • Japan
  • New Zealand
  • South Africa (Granted 30 November 2022)
  • US (Granted 15 February 2022)
  • US divisional 1 (Granted 25 April 2023)
  • US divisional 2 (Granted May 2023)

 

Patent family “Specific salts and polymorphs of 5-HT2A agonists”
International filing date: 5 May 2022.

Composition of matter patent covering specific salts and polymorphs of lead compounds. Positive International Preliminary Report on Patentability received (IPRP)

  • Australia
  • Brazil
  • Canada
  • China
  • Europe
  • India
  • Japan
  • US

Our patents have been developed in close collaboration with COPA Copenhagen Patents K/S.